Biogen Reports Q3 2026 Results, Raises EPS Guidance
Biogen reported adjusted Q3 2026 EPS of $2.62 and revenue of $2.80 billion, above FactSet consensus estimates of $1.99 and $2.63 billion, respectively. It raised the low end of its fiscal 2026 non-GAAP EPS guidance to $12.20, with a range of $12.20 to $13.00.